Proteon Pharmaceuticals has a novel technology named Fluorescent Cell Chip (FCC). It enables detection of immunomodulatory properties of chemical substances that may become antiinflammatory, antiallergic, immunosuppressive or antitumor drugs. FCC could be applied for detection of potential immunotoxicity in the early phase of drug development. This test requires a small amount of tested compound and provides with essential information within a short period of time, so it can be used for testing libraries of chemical compounds. FCC is based on patent-protected genetically modified cell lines that express fluorescent protein in a way that mimics expression of targeted cytokine genes.
Proteon Pharmaceuticals offers also the whole battery of tests detecting immunotoxicity in vitro. These tests include proliferation assay of human T and B cells, evaluation of the effects of tested substance on expression of surface antigens and the whole blood cytokine assay.
Apart from offering research services, Proteon Pharmaceuticals conducts its own research targeted towards development of the novel pharmaceutical and cosmetic substances, first of which the company intends to introduce to the market within the next three years.